Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

BPC-157 Tendon Injury Mechanism: Comparison Table

Before using the comparison below, understand that BPC-157's efficacy is mechanism-dependent. It doesn't 'boost healing' generically. It addresses specific molecular bottlenecks that limit tendon repair. Comparing it to passive modalities or systemic anti-infl

This comparison does not assign a generated winner or score.

  • Before using the comparison below, understand that BPC-157's efficacy is mechanism-dependent. It doesn't 'boost healing' generically. It addresses specific molecular bottlenecks that limit tendon repair. Comparing it to passive modalities or systemic anti-inflammatories clarifies why timing and co-interventions matter.
  • BPC-157 (subcutaneous)
  • VEGF upregulation, FAK-paxillin activation, FGF-2 signaling
  • 340% increase in capillary density by day 10
  • 70–80% baseline by day 14
  • 85–92% with structured loading
  • Most direct biological intervention for hypovascular tendon tissue. Addresses root cause of delayed healing
  • Platelet-Rich Plasma (PRP)
  • Growth factor release from alpha granules
  • Moderate. Dependent on platelet concentration
  • 50–60% baseline by day 14
  • 70–80%
  • Effective but variable. Quality depends on preparation protocol and baseline platelet count
  • NSAIDs (ibuprofen, naproxen)
  • COX inhibition, reduced prostaglandin synthesis
  • None. May impair angiogenesis
  • Delayed. Anti-inflammatory effect suppresses early fibroblast activity
  • 55–65%
  • Reduces pain but delays structural recovery. Contraindicated during proliferation phase
  • Physical therapy alone
  • Mechanical loading, eccentric exercise
  • Indirect. Shear stress upregulates VEGF modestly
  • 40–50% baseline by day 14
  • 60–70%
  • Essential for remodeling but insufficient without vascular support during proliferation
  • Corticosteroid injection
  • Glucocorticoid receptor activation, broad immunosuppression
  • Suppressed. Inhibits VEGF expression
  • Suppressed. Collagen synthesis inhibited for 2–4 weeks post-injection
  • 40–55%
  • Short-term pain relief but long-term structural harm. Avoid during active recovery
More references

Related material